Patient monitoring through liquid biopsies using circulating tumor DNA

International Journal of Cancer

Volumn 141, Issue 5, 2017, Pages 887-896

  Ulz, Peter ^a   Heitzer, Ellen ^a,b   Geigl, Jochen B ^a   Speicher, Michael R ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BIOTECHMED GRAZ   (Austria)

Author keywords

circulating tumor DNA; detection limits; liquid biopsy; tumor evolution models; tumor monitoring

Indexed keywords

DNA; TUMOR MARKER;

ARTICLE; BRANCHING EVOLUTION; CELL HETEROGENEITY; CIRCULATING TUMOR CELL; DISEASE COURSE; FOCAL AMPLIFICATION; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; HETEROZYGOSITY; HUMAN; LINEAR EVOLUTION; LIQUID BIOPSY; NEXT GENERATION SEQUENCING; PATIENT MONITORING; PLASMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOMATIC COPY NUMBER CHANGE; SOMATIC MUTATION; TUMOR MODEL; WHOLE EXOME SEQUENCING; BIOPSY; BLOOD; GENETICS; PROCEDURES; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; BIOPSY; DNA, NEOPLASM; HUMANS; NEOPLASTIC CELLS, CIRCULATING;

EID: 85019707328     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30759     Document Type: Article

References (80)

1. Ashley EA. Towards precision medicine. Nat Rev Genet 2016;17:507–22.
2. Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell 2017;168:584–99.
3. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011;331:1553–8.
4. Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol 2016;17:e81–6.
5. Prasad V. Perspective: The precision-oncology illusion. Nature 2016;537:S63.
6. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene 2016;35:1216–24.
7. Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet). Cancer Cell 2017;31:172–9.
8. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013;59:110–8.
9. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer 2014;14:623–31.
10. Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016;6:479–91.
11. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014;4:650–61.
12. Yu M, Stott S, Toner M, et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011;192:373–82.
13. Wan JC, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17:223–38.
14. Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol, in press.
15. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 2015;61:112–23.
16. Heitzer E, Ulz P, Geigl JB, et al. Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies. Mol Oncol 2016;10:494–502.
17. Diaz LA, Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579–86.
18. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426–37.
19. Perakis S, Speicher MR. Emerging concepts in liquid biopsies. BMC Med 2017;15:75.
20. Bach DH, Hong JY, Park HJ, et al. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer, in press.
21. Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 2016;30:836–48.
22. Moore C, Kosgodage U, Lange S, et al. The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy. Int J Cancer, in press.
23. Belic J, Koch M, Ulz P, et al. Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach. Clin Chem 2015;61:838–49.
24. Heidary M, Auer M, Ulz P, et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 2014;16:421.
25. Heitzer E, Auer M, Hoffmann EM, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer 2013;133:346–56.
26. Heitzer E, Ulz P, Belic J, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013;5:30.
27. Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma dna sequencing. PLoS Genet 2014;10:e1004271.
28. Ulz P, Belic J, Graf R, et al. Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. Nat Commun 2016;7:12008.
29. Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013;73:2965–75.
30. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
31. Diaz LA, Jr., Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537–40.
32. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102:16368–73.
33. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
34. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532–6.
35. Murtaza M, Dawson SJ, Pogrebniak K, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 2015;6:8760.
36. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108–12.
37. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548–54.
38. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:413–21.
39. Ulz P, Thallinger GG, Auer M, et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet 2016;48:1273–8.
40. Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci USA 2013;110:1999–2004.
41. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525–32.
42. Vogelstein B, Kinzler KW. The path to cancer—three strikes and you're out. N Engl J Med 2015;373:1895–8.
43. Tomasetti C, Marchionni L, Nowak MA, et al. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci USA 2015;112:118–23.
44. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017;168:613–28.
45. Gerlinger M, McGranahan N, Dewhurst SM, et al. Cancer: evolution within a lifetime. Annu Rev Genet 2014;48:215–36.
46. Davis A, Gao R, Navin N. Tumor evolution: Linear, branching, neutral or punctuated? Biochim Biophys Acta, in press.
47. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–67.
48. Yates LR, Gerstung M, Knappskog S, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 2015;21:751–9.
49. Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014;6:254ra125.
50. Gao R, Davis A, McDonald TO, et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet 2016;48:1119–30.
51. Sottoriva A, Kang H, Ma Z, et al. A big bang model of human colorectal tumor growth. Nat Genet 2015;47:209–16.
52. Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014;512:155–60.
53. Williams MJ, Werner B, Barnes CP, et al. Identification of neutral tumor evolution across cancer types. Nat Genet 2016;48:238–44.
54. Santaguida S, Amon A. Short- and long-term effects of chromosome mis-segregation and aneuploidy. Nat Rev Mol Cell Biol 2015;16:473–85.
55. Geigl JB, Obenauf AC, Schwarzbraun T, et al. Defining 'chromosomal instability'. Trends Genet 2008;24:64–9.
56. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899–905.
57. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013;45:1134–40.
58. Davoli T, Uno H, Wooten EC, et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017;355.
59. Ulz P, Heitzer E, Speicher MR. Co-occurrence of MYC amplification and TP53 mutations in human cancer. Nat Genet 2016;48:104–6.
60. Turner KM, Deshpande V, Beyter D, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 2017;543:122–5.
61. Leung F, Kulasingam V, Diamandis EP, et al. Circulating tumor DNA as a cancer biomarker: fact or fiction? Clin Chem 2016;62:1054–60.
62. Wall JD, Tang LF, Zerbe B, et al. Estimating genotype error rates from high-coverage next-generation sequence data. Genome Res 2014;24:1734–9.
63. Costello M, Pugh TJ, Fennell TJ, et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res 2013;41:e67.
64. Chen G, Mosier S, Gocke CD, et al. Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol Diagn Ther 2014;18:587–93.
65. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 2016;34:547–55.
66. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA 1999;96:9236–41.
67. Kinzler K, Vogelstein B. Necessity is the mother of invention: the development of digital genomics. Clin Chem 2016;62:1668–9.
68. Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA 2011;108:9530–5.
69. Jabara CB, Jones CD, Roach J, et al. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA 2011;108:20166–71.
70. Schmitt MW, Kennedy SR, Salk JJ, et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA 2012;109:14508–13.
71. Hiatt JB, Pritchard CC, Salipante SJ, et al. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res 2013;23:843–54.
72. Peng Q, Vijaya Satya R, Lewis M, et al. Reducing amplification artifacts in high multiplex amplicon sequencing by using molecular barcodes. BMC Genomics 2015;16:589.
73. Kennedy SR, Schmitt MW, Fox EJ, et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc 2014;9:2586–606.
74. Sun K, Jiang P, Chan KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci USA 2015;112:E5503–12.
75. Lehmann-Werman R, Neiman D, Zemmour H, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci USA 2016;113:E1826–34.
76. Guo S, Diep D, Plongthongkum N, et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet 2017;49:635–42.
77. Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016;164:57–68.
78. Lo YM, Chan KC, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010;2:61ra91.
79. Lemos H, Huang L, McGaha T, et al. STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy? Exp Rev Clin Immunol 2015;11:155–65.
80. Nishimoto S, Fukuda D, Higashikuni Y, et al. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci Adv 2016;2:e1501332.